Trending...
- Rep. Gina H. Curry and Dr. Conan Tu Inspire at Kopp Foundation for Diabetes Hybrid Fundraising Gala and National Leadership Forum
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
- Mensa Members Put Brainpower to Work for Literacy
WESTON, Fla., May 28, 2024 ~ Cantex Pharmaceuticals, Inc. has recently announced that their drug, azeliragon, will be featured in four abstracts at the 2024 ASCO Annual Meeting in Chicago. The company, which focuses on developing transformative therapies for cancer and other life-threatening medical conditions, is excited to showcase the progress of their clinical investigations at leading cancer centers.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
- LSC Destruction Launches Cutting-Edge Cryptocurrency Scanning to Hard Drive Destruction Services
- Mayor Brandon Johnson Presents The Protecting Chicago Budget
- Hidden Dangers of "Cash for Keys" Offers What Homeowners Should Know Before Agreeing to Leave
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
- Podcast for Midlife Women Entrepreneurs Celebrates 100th Episode with Rhea Lana's Founder and CEO
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Chicago: Mayor Brandon Johnson, BACP Announces Request For Proposals For Driver Resource Center
- Mayor Brandon Johnson, Department of Streets and Sanitation, And Chicago Public Library Expand Food Scrap Drop-Off Program To 13 New Library Locations
- Mayor Brandon Johnson Announces the Return Of "Chicago Fall Fest" From Oct. 17-Nov. 2, Featuring Hundreds Of City-Supported Events For Youth and All Residents
- Predatory Refinancing: How Homeowners Fall Into the Equity Trap Without Realizing It
- UK Website Launches "Toy Time Machine" — Find Your Childhood Christmas Toy in One Click
- Stay Safe in Style: The DR. ORGANIZER Personal Purse Alarm Delivers Powerful Protection in a Compact Design
- The Tiny Kitchen Tool That Solves a Big Cooking Headache
- Why Every Dog Deserves a Milo's Choice Towel
- The Secret to Shoes That Actually Fit: Meet the Little Toe Guard
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- Thread Advisory Group Launches to Help Retailers Turn Strategy Into Lasting Results
- QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI
- New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
- Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
- The Son I Knew Too Late: Turning Grief into Guidance
- BCFoods Announces Expansion to New Warehouse Facility in Bolingbrook, Illinois
- Eagle Lasers USA Launches New Website to Empower American Metal Fabricators with Next-Generation Fiber Laser Cutting Solutions
- White Glove Restoration Sends "Help in Boxes" to Support Communities in Ghana